Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Samir H. Barghout"'
Autor:
Safa Majeed, Mansi K. Aparnathi, Kevin C.J. Nixon, Vidhyasagar Venkatasubramanian, Fariha Rahman, Lifang Song, Jessica Weiss, Ranya Barayan, Vijithan Sugumar, Samir H. Barghout, Joel D. Pearson, Rod Bremner, Aaron D. Schimmer, Ming S. Tsao, Geoffrey Liu, Benjamin H. Lok
Publikováno v:
Clinical Cancer Research. 28:1966-1978
Purpose: Small cell lung cancer (SCLC) is an aggressive disease with an overall 5-year survival rate of less than 10%. Treatment for SCLC with cisplatin/etoposide chemotherapy (C/E) ± radiotherapy has changed modestly over several decades. The ubiqu
Autor:
Samir H. Barghout
Publikováno v:
Anti-Cancer Agents in Medicinal Chemistry. 21:214-230
Drug discovery in the scope of cancer therapy has been focused on conventional agents that nonselectively induce DNA damage or selectively inhibit the activity of key oncogenic molecules without affecting their protein levels. An emerging therapeutic
Autor:
Samir H. Barghout
Publikováno v:
Anti-cancer agents in medicinal chemistry. 22(15)
Abstract: Proteolysis targeting chimeras (PROTACs) are an emerging class of targeted protein degraders that coopt the intracellular degradation machinery to selectively deplete their respective targets. PROTACs act as bifunctional degraders that comp
Autor:
Zachary Blatman, Rose Hurren, Neil MacLean, Ahmed Aman, Taira Kiyota, Kazem Nouri, Rima Al-awar, Moustafa Abohawya, Mehakpreet Saini, Karen Arevalo, Samir H. Barghout, Aaron D. Schimmer, Troy Ketela, Geethu E. Thomas
Publikováno v:
JCI Insight, Vol 6, Iss 5 (2021)
JCI Insight
JCI Insight
TAK-243 is a first-in-class inhibitor of ubiquitin-like modifier activating enzyme 1 that catalyzes ubiquitin activation, the first step in the ubiquitylation cascade. Based on its preclinical efficacy and tolerability, TAK-243 has been advanced to p
Autor:
Aaron D. Schimmer, Samir H. Barghout
Publikováno v:
Pharmacological reviews. 73(1)
Post-translational modifications of cellular substrates with ubiquitin and ubiquitin-like proteins (UBLs), including ubiquitin, SUMOs, and neural precursor cell-expressed developmentally downregulated protein 8, play a central role in regulating many
Autor:
Samir H. Barghout, Aaron D. Schimmer
Publikováno v:
Oncotarget